Linked Life Data

9688958

Source:http://linkedlifedata.com/resource/pubmed/id/9688958

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1 Pt 2
pubmed:dateCreated
1998-8-27
pubmed:abstractText
The nonapeptide bradykinin (BK) has been implicated as the mediator of the beneficial effect of angiotensin-converting enzyme inhibitors on insulin-stimulated glucose transport in insulin-resistant skeletal muscle. In the present study, the effects of chronic in vivo BK treatment of obese Zucker (fa/fa) rats, a model of glucose intolerance and severe insulin resistance, on whole body glucose tolerance and skeletal muscle glucose transport activity stimulated by insulin or contractions were investigated. BK was administered subcutaneously (twice daily at 40 microg/kg body wt) for 14 consecutive days. Compared with a saline-treated obese group, the BK-treated obese animals had significantly (P < 0.05) lower fasting plasma levels of insulin (20%) and free fatty acids (26%), whereas plasma glucose was not different. During a 1 g/kg body wt oral glucose tolerance test, the glucose and insulin responses [incremental areas under the curve (AUC)] were 21 and 29% lower, respectively, in the BK-treated obese group. The glucose-insulin index, the product of the glucose and insulin AUCs and an indirect index of in vivo insulin action, was 52% lower in the BK-treated obese group compared with the obese control group. Moreover, 2-deoxyglucose uptake in the isolated epitrochlearis muscle stimulated by a maximally effective dose of insulin (2 mU/ml) was 52% greater in the BK-treated obese group. Contraction-stimulated (10 tetani) 2-deoxyglucose uptake was also enhanced by 35% as a result of the BK treatment. In conclusion, these findings indicate that in the severely insulin-resistant obese Zucker rat, chronic in vivo treatment with BK can significantly improve whole body glucose tolerance, possibly as a result of the enhanced insulin-stimulated skeletal muscle glucose transport activity observed in these animals.
pubmed:keyword
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0002-9513
pubmed:author
pubmed:issnType
Print
pubmed:volume
275
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
R40-5
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:9688958-Animals, pubmed-meshheading:9688958-Blood Glucose, pubmed-meshheading:9688958-Body Weight, pubmed-meshheading:9688958-Bradykinin, pubmed-meshheading:9688958-Citrate (si)-Synthase, pubmed-meshheading:9688958-Drug Administration Schedule, pubmed-meshheading:9688958-Electric Stimulation, pubmed-meshheading:9688958-Fatty Acids, Nonesterified, pubmed-meshheading:9688958-Female, pubmed-meshheading:9688958-Glucose, pubmed-meshheading:9688958-Glucose Tolerance Test, pubmed-meshheading:9688958-Glucose Transporter Type 4, pubmed-meshheading:9688958-Heart, pubmed-meshheading:9688958-Hexokinase, pubmed-meshheading:9688958-Injections, Subcutaneous, pubmed-meshheading:9688958-Insulin, pubmed-meshheading:9688958-Insulin Resistance, pubmed-meshheading:9688958-Monosaccharide Transport Proteins, pubmed-meshheading:9688958-Muscle, Skeletal, pubmed-meshheading:9688958-Muscle Contraction, pubmed-meshheading:9688958-Muscle Proteins, pubmed-meshheading:9688958-Obesity, pubmed-meshheading:9688958-Organ Size, pubmed-meshheading:9688958-Rats, pubmed-meshheading:9688958-Rats, Zucker, pubmed-meshheading:9688958-Time Factors
pubmed:year
1998
pubmed:articleTitle
Effect of chronic bradykinin administration on insulin action in an animal model of insulin resistance.
pubmed:affiliation
Muscle Metabolism Laboratory, Department of Physiology, University of Arizona College of Medicine, Tucson, Arizona 85721-0093, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't